Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus paclitaxel with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +92 locations
Conditions: Lung Cancer
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin plus fluorouracil are more effective than paclitaxel plus cisplatin in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients with advanced head and neck cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: MBCCOP - University of South Alabama, Mobile, Alabama +86 locations
Conditions: Head and Neck Cancer
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with bryostatin 1 plus paclitaxel and cisplatin in treating patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of estramustine, paclitaxel, and carboplatin in treating patients with advanced prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 and paclitaxel in treating patients who have locally advanced or metastatic esophageal cancer or stomach cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Albert Einstein Clinical Cancer Center, Bronx, New York +1 locations
Conditions: Esophageal Cancer, Gastric Cancer
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast can... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining paclitaxel and L-778,123 in treating patients who have recurrent or refractory solid tumors or lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining flavopiridol and paclitaxel in treating patients who have locally advanced or metastatic esophageal cancer that has not responded to previous paclitaxel therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Esophageal Cancer
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with paclitaxel and cisplatin plus flavopiridol in treating patients who have refractory or recurrent solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced, refractory, or recurrent cervical or vaginal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
06/19/2013
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama +49 locations
Conditions: Cervical Cancer, Vaginal Cancer
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill the tumor cells. Combining chemotherapy with interleukin-12 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with interleukin-12 in treating patients who have AIDS-related Kaposi's sa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Sarcoma